

Applicants: Short et al.
Application No: 10/599,943
Amendment
Docket No.: P-7735 (102-682 PCT/US/RCE)
Page 2

AMENDMENTS TO THE CLAIMS:

The following list of claims will replace all prior versions, and listings, of claims. Please amend the claims as follows:

1. (Currently Amended) A method for the selective disassociation of at least one glycosaminoglycan biological entity bound to a plasma polymerized surface of an organic monomer including an allylamine, said method comprising:
contacting said surface with at least one agent having a salt concentration of about 500 mM NaCl to about 2 M NaCl, wherein said agent provides for selective disassociation of said bound glycosaminoglycan entity from said plasma polymerized surface.
- 2.-5. (Cancelled).
6. (Currently Amended) A method according to Claim 1 2 wherein said carbohydrate glycosaminoglycan is a sulphated biomolecule.
7. (Currently Amended) A method according to Claim 1 5 wherein said glycosaminoglycan is selected from the group consisting of: hyaluronan; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; and keratan sulphate.
- 8.-11. (Cancelled).
12. (Previously Presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile acid.
13. (Previously Presented) A method according to Claim 12 wherein said surface comprises at least 5% of said volatile acid.

Applicants: Short et al.
Application No: 10/599,943
Amendment
Docket No.: P-7735 (102-682 PCT/US/RCE)
Page 3

14. (Previously Presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile alcohol.

15. (Previously Presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile amine.

16. (Previously Presented) A method according to Claim 1 wherein said surface comprises a mixture of volatile acid and volatile hydrocarbon.

17.-25. (Cancelled).

26. (Previously Presented) A method according to Claim 6 wherein said sulphated biomolecule is selected from the group consisting of: dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; and keratan sulphate.

27. (Cancelled).

28. (Previously Presented) A method according to claim 1, wherein said agent has a salt concentration of about 500 mM NaCl to about 1 M NaCl.

29. (Previously Presented) A method according to claim 1, wherein said agent has a salt concentration of about 750 mM NaCl to about 1 M NaCl.

30. (Cancelled).

31. (Previously Presented) A method according to claim 1, wherein said agent has a salt concentration of about 500 mM NaCl to about 750 mM NaCl.